This document is an international evidence-based guideline on the diagnosis and management
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …

Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …

Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …

Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …

Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS)
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …

Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

The ability to perturb genes in human cells is crucial for elucidating gene function and holds
great potential for finding therapeutic targets for diseases such as cancer. To extend the …

The natural history of idiopathic pulmonary fibrosis (IPF) has been characterized as a steady,
predictable decline in lung function over time. Recent evidence suggests that some …

Background Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality
rate. Because the signaling pathways activated by several tyrosine kinase receptors have …